KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherReceivables RefundsShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Sarepta Therapeutics (SRPT) EBIAT (2016 - 2025)

Sarepta Therapeutics has reported EBIAT over the past 15 years, most recently at -$412.2 million for Q4 2025.

  • For Q4 2025, EBIAT fell 359.18% year-over-year to -$412.2 million; the TTM value through Dec 2025 reached -$713.4 million, down 403.27%, while the annual FY2025 figure was -$713.4 million, 403.27% down from the prior year.
  • EBIAT for Q4 2025 was -$412.2 million at Sarepta Therapeutics, down from -$50.6 million in the prior quarter.
  • Over five years, EBIAT peaked at $196.9 million in Q2 2025 and troughed at -$516.8 million in Q1 2023.
  • A 5-year average of -$106.8 million and a median of -$66.0 million in 2021 define the central range for EBIAT.
  • On a YoY basis, EBIAT climbed as much as 2947.86% in 2025 and fell as far as 1338.98% in 2025.
  • Year by year, EBIAT stood at -$122.0 million in 2021, then grew by 10.44% to -$109.2 million in 2022, then skyrocketed by 141.79% to $45.7 million in 2023, then surged by 248.37% to $159.0 million in 2024, then plummeted by 359.18% to -$412.2 million in 2025.
  • Business Quant data shows EBIAT for SRPT at -$412.2 million in Q4 2025, -$50.6 million in Q3 2025, and $196.9 million in Q2 2025.